Cargando…

Periprocedural Hydrogen Sulfide Therapy Improves Vascular Remodeling and Attenuates Vein Graft Disease

BACKGROUND: Failure rates after revascularization surgery remain high, both in vein grafts (VG) and arterial interventions. One promising approach to improve outcomes is endogenous upregulation of the gaseous transmitter‐molecule hydrogen sulfide, via short‐term dietary restriction. However, strict...

Descripción completa

Detalles Bibliográficos
Autores principales: Kip, Peter, Tao, Ming, Trocha, Kaspar M., MacArthur, Michael R., Peters, Hendrika A. B., Mitchell, Sarah J., Mann, Charlotte G., Sluiter, Thijs J., Jung, Jonathan, Patterson, Suzannah, Quax, Paul H. A., de Vries, Margreet R., Mitchell, James R., Keith Ozaki, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7763704/
https://www.ncbi.nlm.nih.gov/pubmed/33146045
http://dx.doi.org/10.1161/JAHA.120.016391
_version_ 1783628081538269184
author Kip, Peter
Tao, Ming
Trocha, Kaspar M.
MacArthur, Michael R.
Peters, Hendrika A. B.
Mitchell, Sarah J.
Mann, Charlotte G.
Sluiter, Thijs J.
Jung, Jonathan
Patterson, Suzannah
Quax, Paul H. A.
de Vries, Margreet R.
Mitchell, James R.
Keith Ozaki, C.
author_facet Kip, Peter
Tao, Ming
Trocha, Kaspar M.
MacArthur, Michael R.
Peters, Hendrika A. B.
Mitchell, Sarah J.
Mann, Charlotte G.
Sluiter, Thijs J.
Jung, Jonathan
Patterson, Suzannah
Quax, Paul H. A.
de Vries, Margreet R.
Mitchell, James R.
Keith Ozaki, C.
author_sort Kip, Peter
collection PubMed
description BACKGROUND: Failure rates after revascularization surgery remain high, both in vein grafts (VG) and arterial interventions. One promising approach to improve outcomes is endogenous upregulation of the gaseous transmitter‐molecule hydrogen sulfide, via short‐term dietary restriction. However, strict patient compliance stands as a potential translational barrier in the vascular surgery patient population. Here we present a new therapeutic approach, via a locally applicable gel containing the hydrogen sulfide releasing prodrug (GYY), to both mitigate graft failure and improve arterial remodeling. METHODS AND RESULTS: All experiments were performed on C57BL/6 (male, 12 weeks old) mice. VG surgery was performed by grafting a donor‐mouse cava vein into the right common carotid artery of a recipient via an end‐to‐end anastomosis. In separate experiments arterial intimal hyperplasia was assayed via a right common carotid artery focal stenosis model. All mice were harvested at postoperative day 28 and artery/graft was processed for histology. Efficacy of hydrogen sulfide was first tested via GYY supplementation of drinking water either 1 week before VG surgery (pre‐GYY) or starting immediately postoperatively (post‐GYY). Pre‐GYY mice had a 36.5% decrease in intimal/media+adventitia area ratio compared with controls. GYY in a 40% Pluronic gel (or vehicle) locally applied to the graft/artery had decreased intimal/media area ratios (right common carotid artery) and improved vessel diameters. GYY‐geltreated VG had larger diameters at both postoperative days 14 and 28, and a 56.7% reduction in intimal/media+adventitia area ratios. Intimal vascular smooth muscle cell migration was decreased 30.6% after GYY gel treatment, which was reproduced in vitro. CONCLUSIONS: Local gel‐based treatment with the hydrogen sulfide‐donor GYY stands as a translatable therapy to improve VG durability and arterial remodeling after injury.
format Online
Article
Text
id pubmed-7763704
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-77637042020-12-28 Periprocedural Hydrogen Sulfide Therapy Improves Vascular Remodeling and Attenuates Vein Graft Disease Kip, Peter Tao, Ming Trocha, Kaspar M. MacArthur, Michael R. Peters, Hendrika A. B. Mitchell, Sarah J. Mann, Charlotte G. Sluiter, Thijs J. Jung, Jonathan Patterson, Suzannah Quax, Paul H. A. de Vries, Margreet R. Mitchell, James R. Keith Ozaki, C. J Am Heart Assoc Original Research BACKGROUND: Failure rates after revascularization surgery remain high, both in vein grafts (VG) and arterial interventions. One promising approach to improve outcomes is endogenous upregulation of the gaseous transmitter‐molecule hydrogen sulfide, via short‐term dietary restriction. However, strict patient compliance stands as a potential translational barrier in the vascular surgery patient population. Here we present a new therapeutic approach, via a locally applicable gel containing the hydrogen sulfide releasing prodrug (GYY), to both mitigate graft failure and improve arterial remodeling. METHODS AND RESULTS: All experiments were performed on C57BL/6 (male, 12 weeks old) mice. VG surgery was performed by grafting a donor‐mouse cava vein into the right common carotid artery of a recipient via an end‐to‐end anastomosis. In separate experiments arterial intimal hyperplasia was assayed via a right common carotid artery focal stenosis model. All mice were harvested at postoperative day 28 and artery/graft was processed for histology. Efficacy of hydrogen sulfide was first tested via GYY supplementation of drinking water either 1 week before VG surgery (pre‐GYY) or starting immediately postoperatively (post‐GYY). Pre‐GYY mice had a 36.5% decrease in intimal/media+adventitia area ratio compared with controls. GYY in a 40% Pluronic gel (or vehicle) locally applied to the graft/artery had decreased intimal/media area ratios (right common carotid artery) and improved vessel diameters. GYY‐geltreated VG had larger diameters at both postoperative days 14 and 28, and a 56.7% reduction in intimal/media+adventitia area ratios. Intimal vascular smooth muscle cell migration was decreased 30.6% after GYY gel treatment, which was reproduced in vitro. CONCLUSIONS: Local gel‐based treatment with the hydrogen sulfide‐donor GYY stands as a translatable therapy to improve VG durability and arterial remodeling after injury. John Wiley and Sons Inc. 2020-11-04 /pmc/articles/PMC7763704/ /pubmed/33146045 http://dx.doi.org/10.1161/JAHA.120.016391 Text en © 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research
Kip, Peter
Tao, Ming
Trocha, Kaspar M.
MacArthur, Michael R.
Peters, Hendrika A. B.
Mitchell, Sarah J.
Mann, Charlotte G.
Sluiter, Thijs J.
Jung, Jonathan
Patterson, Suzannah
Quax, Paul H. A.
de Vries, Margreet R.
Mitchell, James R.
Keith Ozaki, C.
Periprocedural Hydrogen Sulfide Therapy Improves Vascular Remodeling and Attenuates Vein Graft Disease
title Periprocedural Hydrogen Sulfide Therapy Improves Vascular Remodeling and Attenuates Vein Graft Disease
title_full Periprocedural Hydrogen Sulfide Therapy Improves Vascular Remodeling and Attenuates Vein Graft Disease
title_fullStr Periprocedural Hydrogen Sulfide Therapy Improves Vascular Remodeling and Attenuates Vein Graft Disease
title_full_unstemmed Periprocedural Hydrogen Sulfide Therapy Improves Vascular Remodeling and Attenuates Vein Graft Disease
title_short Periprocedural Hydrogen Sulfide Therapy Improves Vascular Remodeling and Attenuates Vein Graft Disease
title_sort periprocedural hydrogen sulfide therapy improves vascular remodeling and attenuates vein graft disease
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7763704/
https://www.ncbi.nlm.nih.gov/pubmed/33146045
http://dx.doi.org/10.1161/JAHA.120.016391
work_keys_str_mv AT kippeter periproceduralhydrogensulfidetherapyimprovesvascularremodelingandattenuatesveingraftdisease
AT taoming periproceduralhydrogensulfidetherapyimprovesvascularremodelingandattenuatesveingraftdisease
AT trochakasparm periproceduralhydrogensulfidetherapyimprovesvascularremodelingandattenuatesveingraftdisease
AT macarthurmichaelr periproceduralhydrogensulfidetherapyimprovesvascularremodelingandattenuatesveingraftdisease
AT petershendrikaab periproceduralhydrogensulfidetherapyimprovesvascularremodelingandattenuatesveingraftdisease
AT mitchellsarahj periproceduralhydrogensulfidetherapyimprovesvascularremodelingandattenuatesveingraftdisease
AT manncharlotteg periproceduralhydrogensulfidetherapyimprovesvascularremodelingandattenuatesveingraftdisease
AT sluiterthijsj periproceduralhydrogensulfidetherapyimprovesvascularremodelingandattenuatesveingraftdisease
AT jungjonathan periproceduralhydrogensulfidetherapyimprovesvascularremodelingandattenuatesveingraftdisease
AT pattersonsuzannah periproceduralhydrogensulfidetherapyimprovesvascularremodelingandattenuatesveingraftdisease
AT quaxpaulha periproceduralhydrogensulfidetherapyimprovesvascularremodelingandattenuatesveingraftdisease
AT devriesmargreetr periproceduralhydrogensulfidetherapyimprovesvascularremodelingandattenuatesveingraftdisease
AT mitchelljamesr periproceduralhydrogensulfidetherapyimprovesvascularremodelingandattenuatesveingraftdisease
AT keithozakic periproceduralhydrogensulfidetherapyimprovesvascularremodelingandattenuatesveingraftdisease